Leyden Labs is a biotech company working to protect people against respiratory viruses. It is leveraging its Mucosal Protection Platform to develop a portfolio of broadly protective nasal spray candidates against influenza, coronaviruses, and other respiratory viruses by administering antibodies directly to the respiratory mucosa.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round | |
|---|---|---|---|
| €40 M | Jun, 2026 | unspecified | View |
Industries
Frequently Asked Questions
Where is Leyden Labs located?
Leyden Labs is located in Leiden, Netherlands.
What industries does Leyden Labs operate in?
Leyden Labs operates in the following industries: biotechnology, healthcare.
How much total funding has Leyden Labs raised?
Leyden Labs has raised a total of $40,000,000.
Who are the investors in Leyden Labs?
The investors in Leyden Labs are: European Innovation Council (EIC) Fund, Invest-NL, Gates Foundation, ClavystBio.
What is Leyden Labs?
Leyden Labs is a clinical-stage biotechnology company founded in 2020 and based in the Netherlands that develops innovative nasal sprays to protect against respiratory viruses.
What does Leyden Labs do?
Leyden Labs utilizes its Mucosal Protection Platform to deliver antibodies directly to the nasal mucosa, providing a non-vaccine approach to stop respiratory viruses like influenza and coronaviruses at their point of entry.
What is the primary goal of Leyden Labs?
The goal of Leyden Labs is to free people from the threat of respiratory viruses by providing immediate, broad protection that prevents infection and transmission, particularly for vulnerable groups.
Is Leyden Labs still active?
Yes, Leyden Labs is active and recently secured significant funding in 2026 to advance its clinical programs and develop its nasal spray technology.